Axiom Research, LLC

The trials here

What the 12 trials at this site are about, from their registry records.

Conditions

• Migraine8 trials
• Alzheimer disease2 trials

Phase

• Phase 38 trials
• Phase 22 trials
• Phase 2/31 trial
• Phase 41 trial

Status

• Completed4 trials
• Terminated4 trials
• Active, not recruiting2 trials
• Recruiting2 trials

Lead sponsor

• AEON Biopharma, Inc.2 trials
• Biohaven Pharmaceuticals, Inc.2 trials
• Cassava Sciences, Inc.2 trials
• Ipsen2 trials
• Pfizer2 trials
• and 1 more

Running trials

• Recruiting

  A Long-Term Safety Study of Elismetrep (K-304) in the Acute Treatment of Migraine

  NCT07674654· Phase 3· TriGemX Bio, Inc.· Source

  Contact: Annemarie Vance

• Recruiting

  A Study to Evaluate the Efficacy and Safety of Elismetrep (K-304) in the Acute Treatment of Migraine

  NCT07645924· Phase 3· TriGemX Bio, Inc.· Source

  Contact: Annemarie Vance

• Active, not recruiting

  A Study to Evaluate the Effectiveness and Safety of Dysport® for the Prevention of Chronic Migraine in Adults

  NCT06047444· Phase 3· Ipsen· Source

• Active, not recruiting

  A Study to Evaluate the Effectiveness and Safety of Dysport® for the Prevention of Episodic Migraine in Adults

  NCT06047457· Phase 3· Ipsen· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Migraine2 recruiting

Closed trials

• Terminated

  Open-label Extension for Phase 3 Clinical Trials of Simufilam

  NCT05575076· Phase 3· Cassava Sciences, Inc.· Source

• Completed

  Efficacy and Safety Study of Rimegepant in Episodic Migraine Prevention With Multiple Dosing Regimens

  NCT05217927· Phase 4· Pfizer· Source

• Completed

  Simufilam 100 mg for Mild-to-Moderate Alzheimer's Disease

  NCT04994483· Phase 3· Cassava Sciences, Inc.· Source

• Terminated

  Extension Study of ABP-20001 to Evaluate Safety and Efficacy of Repeat Treatments of ABP-450 for Migraine Prevention

  NCT05016661· Phase 2· AEON Biopharma, Inc.· Source

• Terminated

  Long-term Safety Study of Adjunctive Troriluzole in Subjects With Obsessive Compulsive Disorder

  NCT04708834· Phase 3· Biohaven Pharmaceuticals, Inc.· Source

• Terminated

  A Study to Evaluate the Efficacy and Safety of Oral Zavegepant in Migraine Prevention

  NCT04804033· Phase 2/3· Pfizer· Source

• Completed

  Investigation of Safety and Efficacy of ABP-450 for Migraine Prevention in Adults

  NCT04845178· Phase 2· AEON Biopharma, Inc.· Source

• Completed

  Efficacy and Safety Study of Adjunctive Troriluzole in Obsessive Compulsive Disorder

  NCT04641143· Phase 3· Biohaven Pharmaceuticals, Inc.· Source